{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-111750","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.468707+00:00","generated_at":"2026-06-09T08:02:05.197601+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx Q3 revenue up 70% to $10.5M, raises FY2023 revenue guidance","bullets":["Revenue $10.5M (+70% YoY); U.S. HF revenue $9.4M (+92% YoY).","Net loss $9.0M ($0.43/sh) vs $9.8M ($0.48/sh) in Q3 2022; cash burn improved to $8.2M from $13.0M in Q2.","Active implanting centers 159 (+75% YoY); sales territories grew to 35.","FY2023 revenue guidance raised to $38.5M-$39.0M (from $37.0M-$38.5M); Q4 revenue expected $10.5M-$11.0M.","CMS advisory panel unanimously recommended higher Barostim payment code; final rule expected late Nov."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-111750","json":"https://secwatch.observer/filing/0001104659-23-111750.json","markdown":"https://secwatch.observer/filing/0001104659-23-111750.md","text":"https://secwatch.observer/filing/0001104659-23-111750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923111750/0001104659-23-111750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923111750/tm2329194d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:02:05.197601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31296924f3d41581d4ff0df2c148aae8554a4a16","claim":"CVRx, Inc. reported the third quarter of 2023 results: revenue $10.5 million, net income $9.0 million, EPS $0.43 per share.","evidence_excerpt":"cardiovascular diseases, today announced its financial and operating results for the third quarter of 2023. Recent Highlights · Total revenue for the third quarter of 2023 was $10.5 million, an increase of 70% over the prior year quarter · U.S. Heart Failure (HF) revenue for the third quarter of 2023 was $9.4 million, an increase of 92% over the prior year quarter ·","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923111750/0001104659-23-111750-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$10.5 million"},{"label":"Net income","value":"$9.0 million"},{"label":"EPS","value":"$0.43 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}